On Tuesday, Intellia Therapeutics Inc (NASDAQ: NTLA) opened lower -3.98% from the last session, before settling in for the closing price of $6.54. Price fluctuations for NTLA have ranged from $5.90 to $28.18 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 15.68% over the last five years. Company’s average yearly earnings per share was noted 11.04% at the time writing. With a float of $97.42 million, this company’s outstanding shares have now reached $102.03 million.
The firm has a total of 403 workers. Let’s measure their productivity. In terms of profitability, gross margin is 91.17%, operating margin of -923.1%, and the pretax margin is -896.77%.
Intellia Therapeutics Inc (NTLA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Intellia Therapeutics Inc is 5.89%, while institutional ownership is 90.17%. The most recent insider transaction that took place on Mar 04 ’25, was worth 6,104. In this transaction EVP, Chief Technical Officer of this company sold 679 shares at a rate of $8.99, taking the stock ownership to the 95,369 shares. Before that another transaction happened on Mar 04 ’25, when Company’s EVP, General Counsel sold 2,572 for $8.99, making the entire transaction worth $23,122. This insider now owns 111,925 shares in total.
Intellia Therapeutics Inc (NTLA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 11.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.29% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Check out the current performance indicators for Intellia Therapeutics Inc (NTLA). In the past quarter, the stock posted a quick ratio of 5.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.25, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -4.40 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Analysing the last 5-days average volume posted by the [Intellia Therapeutics Inc, NTLA], we can find that recorded value of 4.6 million was better than the volume posted last year of 3.44 million. As of the previous 9 days, the stock’s Stochastic %D was 14.59%. Additionally, its Average True Range was 0.75.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 3.33%, which indicates a significant decrease from 10.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.58% in the past 14 days, which was higher than the 77.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.45, while its 200-day Moving Average is $16.31. Now, the first resistance to watch is $6.83. This is followed by the second major resistance level at $7.39. The third major resistance level sits at $7.74. If the price goes on to break the first support level at $5.92, it is likely to go to the next support level at $5.57. Should the price break the second support level, the third support level stands at $5.01.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
There are currently 103,517K shares outstanding in the company with a market cap of 650.09 million. Presently, the company’s annual sales total 57,880 K according to its annual income of -519,020 K. Last quarter, the company’s sales amounted to 12,870 K and its income totaled -128,900 K.
